Our study found that AIM2 overexpression enhances the therapeutic efficacy of BCG immunotherapy in mice, with a more robust infiltration of CD11b+ neutrophils, smaller tumor size and weight, and longer survival time. This evidence concerns the gene ITGAM and neoplasm.